Zealand Pharma announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending granting marketing authorization for dasiglucagon solution for injection in the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus. The positive opinion from the CHMP will be referred to the European Commission for a final decision whether to grant marketing authorization in the European Union. Zealand expects this decision within approximately three months. Dasiglucagon injection was approved by the U.S. FDA in March 2021 under the brand name Zegalogue.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand initiated with Overweight at Cantor ahead of FDA approvals
- Zealand Pharma initiated with an Overweight at Cantor Fitzgerald
- Zealand Pharma upgraded to Hold from Sell at Danske Bank
- ZLDPF Earnings this Week: How Will it Perform?
- Zealand Pharma added to European Conviction List at Goldman Sachs